NASDAQ:MLNDMillendo Therapeutics Stock Price, Forecast & News

Millendo Therapeutics' stock was trading at $6.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MLND shares have decreased by 74.0% and is now trading at $1.71. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Millendo Therapeutics.

Millendo Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Millendo Therapeutics.

Millendo Therapeutics Inc (NASDAQ:MLND) posted its earnings results on Friday, May, 8th. The company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.67) by $0.02. View Millendo Therapeutics' earnings history.

7 brokers have issued 1-year price targets for Millendo Therapeutics' shares. Their forecasts range from $2.00 to $26.00. On average, they anticipate Millendo Therapeutics' stock price to reach $10.14 in the next twelve months. This suggests a possible upside of 493.1% from the stock's current price. View analysts' price targets for Millendo Therapeutics.

News articles about MLND stock have trended very negative on Thursday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Millendo Therapeutics earned a news impact score of -3.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Millendo Therapeutics.

Millendo Therapeutics saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 561,100 shares, an increase of 5.9% from the May 31st total of 529,800 shares. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is currently 0.5 days. Currently, 4.2% of the company's shares are sold short. View Millendo Therapeutics' Current Options Chain.

Some companies that are related to Millendo Therapeutics include Harrow Health (HROW), Rockwell Medical (RMTI), PhaseBio Pharmaceuticals (PHAS), Arbutus Biopharma (ABUS), Sierra Oncology (SRRA), Conatus Pharmaceuticals (CNAT), Inflarx (IFRX), Aldeyra Therapeutics (ALDX), ESSA Pharma (EPIX), Savara (SVRA), Trevi Therapeutics (TRVI), Genprex (GNPX), Celsion (CLSN), Otonomy (OTIC) and Eton Pharmaceuticals (ETON). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Applied Genetic Technologies (AGTC), Aileron Therapeutics (ALRN), Aquestive Therapeutics (AQST), Flexion Therapeutics (FLXN), Galmed Pharmaceuticals (GLMD), Gilead Sciences (GILD), Obseva (OBSV) and Outlook Therapeutics (OTLK).

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MLND stock can currently be purchased for approximately $1.71.

Millendo Therapeutics has a market capitalization of $32.49 million and generates $290,000.00 in revenue each year. The company earns $-44,570,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Millendo Therapeutics employs 37 workers across the globe.

The official website for Millendo Therapeutics is www.millendo.com.

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]